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Parvovirus B19-introduction
Parvovirus B19 (B19) is an erythrovirus and recent studies have classified B19 as a
genotype 1 erythrovirus with genotypes 2 (erythrovirus K71 or A6) and 3 (er-
ythrovirus V9) also present in the human population. B19 is a significant human
pathogen which can cause foetal hydrops and foetal death if maternal infection,
followed by transplacental QA :1foetal infection, occurs during pregnancy. The virus is
also transmitted by inter-personal contact and potentially via blood product ad-
ministration. Symptoms of B19 infection include malaise, rash and anthralgia.
Significantly, maternal B19 infection during pregnancy can be asymptomatic and
so careful monitoring of at-risk pregnancies is recommended. Both antibody- and
cell-mediated immunity play an important role in the anti-viral response and ef-
fective diagnostic test systems, for both B19 antibody and DNA detection, are now
available. B19-induced foetal hydrops can be effectively treated by intrauterine
blood transfusion; however, no vaccine is available to prevent infection at present.
Molecular virology
Human parvovirus B19 (B19) was first identified in 1975 by Yvonne Cossart
(Cossart et al., 1975). The virus was first associated with disease in 1981 when it was
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linked to an aplastic crisis in a patient with sickle-cell disease. Subsequently, B19
has since been shown to be the causative agent of erythema infectiosum (EI) (Fifth
disease of childhood), spontaneous abortion and some forms of acute arthritis
(Anderson et al., 1983; Kinney et al., 1988; Woolf and Cohen, 1995). B19 is ap-
proximately 20 nm in diameter, has a genome of 5.6 kb (Clewley, 1984; Cotmore
and Tattersall, 1984) and is a small, non-enveloped, single-stranded DNA virus.
Like all parvoviruses, the constituent capsid proteins (VP1 and VP2) are arranged
with icosahedral symmetry. The B19 capsid consists of an 83 kDa low-abundance
structural protein, VP1, and a 58 kDa major structural protein, VP2. VP2 makes up
about 95% of total capsid structure with VP1 accounting for the remaining 5%
(Ozawa et al., 1987). The sequences of the two proteins are co-linear and the entire
VP2 sequence is identical to the carboxyl-terminus of VP1. However, VP1 com-
prises an additional 227 amino acids unique to the amino-terminal, the so-called
VP1 unique region (VP1u). To the left of these sequences on the B19 genome is the
open-reading frame for a non-structural protein, NS1 which encodes a 77 kDa
protein. NS1 is a phosphoprotein with important regulatory functions including
transcriptional control (Momoeda et al., 1994a, b), virus replication and also plays
a role in host cell death (Ozawa et al., 1988). NS1 also exhibits DNA-binding
properties (Raab et al., 2002), and a multitude of enzymatic functions including
ATPase, helicase and site-specific endonuclease activity, as well as containing nu-
clear localisation signals (Li and Rhode, 1990; McCarthy et al., 1992; Jindal et al.,
1994; Brown and Young, 1998). It has been demonstrated that B19 NS1 also effects
G(1), but not G(2), arrest in erythroid UT7/Epo-S1 cells (Morita et al., 2003).
A single promoter, p6, is employed by B19 which is capable of differentially
expressing both structural and non-structural genes (Blundell et al., 1987; Ozawa et
al., 1987). The NS1 protein interacts directly with the p6 promoter and with cellular
transcription factors Sp1/Sp3 to effect transcriptional regulation (Raab et al.,
2002). Two additional smaller polypeptides (p7.5 and p11) have been identified, one
encoded by a region near the centre of the B19 genome with a predicted Mr of
7.5 kDa and the other which is encoded at the extreme right-hand end of the
genome of predicted Mr ¼ 11 kDa (St Amand et al., 1991). Spliced transcripts of
both proteins have been detected in infected cells but specific functions have not, as
yet, been assigned to either protein (Luo, 1993).
As a result of the increased interest in, and molecular detection of, parvovirus
B19 a number of new erythrovirus genotypes have been identified. Servant et al.
(2002) has suggested that B19 be classified as a genotype 1 erythrovirus with newly
identified strains A6 (Nguyen et al., 2002) and K71 (Hokynar et al., 2002) classified
as genotypes 2 and erythrovirus V9 (Nguyen et al., 1998) as the prototype genotype
3. Based on inter-genotype phylogenetic relationships between NS1 and VP1u re-
gions, respectively, erythrovirus genotype 3 (erythrovirus variant V9) has been
shown to be the most prevalent erythrovirus in Ghana and appears to divide into
two sub-types (Candotti et al., 2004).
B19 has only been shown to infect humans and replicates in human erythroid
progenitor cells (late erythroid cell precursors and burst-forming erythroid pro-
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genitors (BFU-E)) of the bone marrow and blood, resulting in an inhibition of
erythropoiesis (Mortimer et al., 1983). Brown et al. (1993,1994) elegantly demon-
strated that the restrictive tropism of productive B19 infection is primarily due to
the P blood group antigen, globoside (Gb4). This molecule is a significant cellular
receptor for B19 and is most often found on cells of the erythroid lineage but also
on platelets and tissues from the heart, kidney, lung, liver, endothelium and on
synovia (Cooling et al., 1995; Jordan and DeLoia, 1999). Individuals lacking
erythrocyte P antigens are very rare (1 in 200,000) and exhibit much diminished
susceptibility to B19 infection (Brown et al., 1994; Chipman et al., 1996). However,
the limited tropism of B19 is not fully understood as low-level capsid expression has
actually been observed in non-permissive cells; nonetheless, intracellular factors
unique to erythroid cells are thought to be essential for optimal transcription and
viral replication (Ozawa et al., 1987; Kurpad et al., 1999; Gallinella et al., 2000).
Weigel-Kelley et al. (2001) have demonstrated that the P antigen-expression
level on cell surfaces is not directly related to the efficiency of viral binding. In
addition, despite P antigen expression and viral adherence to the P antigen, some
cell lines could not be transduced with a B19 vector thereby indicating that a co-
receptor is likely to be necessary for B19 entry into human cells. Thus, the presence
of P antigen alone is not sufficient for B19 to gain entry into cells (Weigel-Kelley et
al., 2001) and it has been suggested that multiple b-integrins may additionally
function as co-receptors for B19 cellular uptake (Weigel-Kelley et al., 2003).
In vitro studies of B19 infectivity have been greatly hampered by difficulties in
propagating the virus in vitro. Indeed, no continuous cell line propagating B19 has
been established, due to the cytotoxic nature of the non-structural protein, NS1
(Ozawa et al., 1987; Momoeda et al., 1994 QA :2). However, recent studies have shown
that infection under hypoxic conditions (1%(v/v) O2) causes an upregulation of
B19 expression which is associated with increased viral replication and of infectious
virion production (Pillet et al., 2004). It has been demonstrated that hypoxia-
inducible factor-1 (HIF-1), a key transcription factor involved in the cellular re-
sponse to reduced oxygenation, binds an HIF-binding site (HBS) present in the B19
promoter region (Pillet et al., 2004). In a parallel work, Caillet-Fauquet et al. (2004)
have shown that human plasma containing known amounts of B19 DNA (virus)
could infect the human erythroid cell line KU812F and that under low oxygen
pressure, higher yields of infectious B19 progeny virus and increased viral tran-
scription were observed. These authors also demonstrated that anti-B19 IgG re-
duced B19 infectivity and suggest that system represents a promising model to
study B19 infectivity and infectivity control methodologies.
Transmission of B19 infection most often occurs by personal contact via aer-
osol or respiratory secretions, however contaminated blood products such as clot-
ting factor concentrates are also a source of iatrogenic transmission (Anderson et
al., 1985; Lyon et al., 1989; Williams et al., 1990; Santagostino et al., 1994; Erdman
et al., 1997). Significantly, B19 can also be transmitted transplacentally from an
infected mother to the foetus, on occasion leading to non-immune foetal hydrops
(NIHF), spontaneous abortion or intrauterine foetal death (IUFD) (Clewley et al.,
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1987; Miller et al., 1998; Skjoldebrand-Sparre et al., 2000). A range of vertical
transmission rates for maternal–foetal infection of 7–33% have been reported
(Enders and Biber, 1990; Hall et al., 1990; Yaegashi, 2000). The P blood group
antigen, which acts as a receptor for B19, has been detected on cells of the villous
trophoblast of placental tissues in varying amounts during the course of pregnancy.
In the first trimester, P antigen levels are elevated, begin to decline in the second
trimester and become undetectable by the mid-stages of trimester 3 (Jordan and
DeLoia, 1999). It has been proposed that this high level of globoside receptor on
placental cells in early pregnancy may act as a pathway for maternal–foetus B19
transmission whereby the virus can then infect erythroid precursor cells for rep-
lication. Indeed, Wegner and Jordan (2002 QA :3) have conclusively shown that I
125-
labelled B19 VP2 capsids interact with villous cytotrophoblast cells via the P an-
tigen. Moreover, in a detailed review of viral transmission at the uterine–placental
interface, Pereira et al. (2005) have shown that cytotrophoblasts infected with hu-
man cytomegalovirus exhibit altered differentiation patterns and suggest that such
abberant behaviour may contribute to foetal growth restriction.
Clinical features and prevalence
B19 has been associated with an ever-expanding range of clinical disorders since the
discovery that it is the aetiologic agent of EI, a facial and occasionally body-wide
red rash. It is also associated with complications during pregnancy, acute art-
hropathy, severe disease in immunocompromised patients and transient aplastic
crisis.
General clinical features and chronic infection
Infection with B19 occurs worldwide and cases of infection have been reported in
all seasons. Seroprevalence increases with age and by adulthood at least 70% of the
adult population are B19 IgG seropositive (Cohen and Buckley, 1988). B19 out-
breaks can persist for months in schools as seronegative children represent a sig-
nificant reservoir for B19 infection. Recently infected children therefore are the
main source of transmission in day-care centres due to the relatively large number
of seronegative children and the close contact of children within this environment
(Tuckerman et al., 1986; Grilli et al., 1989). The annual seroconversion rate among
women of childbearing age has been estimated to be 1.5% during endemic periods
and 13% during epidemics (Koch and Adler, 1989; Valeur-Jensen et al., 1999).
B19 infection has also been linked to arthritis and arthralgias, most commonly
in adults but also in children (Reid et al., 1985) as has been documented for the
rubella virus (Lee, 1962). On average, 50% of adult cases reported with EI have
associated joint symptomologies, which may last for up to 1 month (Cassinotti,
1995). B19 arthritis is usually symmetrical and affects mainly the small joints of the
hands, wrists and knees (Reid et al., 1985). It is more common in females and an
estimated 60% of women with symptomatic disease exhibit signs of arthropathy
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(White et al., 1985; Woolf et al., 1989). Symptoms generally diminish within 3
weeks without any permanent joint damage (Woolf et al., 1991), however about
20% of affected women suffer a persistent or recurrent arthropathy. About 75% of
these patients have an associated rash and less than 20% have the typical ‘slapped
cheeks’ facial exanthem. It has been hypothesised that B19-associated arthritis may
be related to certain patient human leucocyte antigen (HLA) haplotypes, with
individuals classified as either HLA DR4 or B27 exhibitied increased susceptibility
(Klouda et al., 1986; Jawad, 1993). At present, it is unclear how B19 produces
symptoms associated with arthritis. Like the appearance of exanthema in EI, ar-
thritis usually occurs after the development of B19-specific antibodies which sug-
gests that symptoms may be due to immune-complex formation. Although the P
antigen is expressed on synovium, it has been shown that synovial membrane cells
are non-permissive to B19 (Miki and Chantler, 1992; Cooling et al., 1995). B19 may
gain entry to B19 receptor positive cells, that are not actively dividing, resulting in
the production of excessive, cytotoxic NS1 (Ozawa et al., 1988). The presence of the
NS1 protein induces the expression of pro-inflammatory cytokines, which could
cause the inflammation and cell damage seen in patients with B19-associated ar-
thritis and other inflammatory and autoimmune disorders which have been asso-
ciated with B19 infection (Moffatt et al., 1996; Mitchell, 2002). The precise
significance of antibodies against the non-structural protein is unclear. Antibodies
specific for NS1 were found in individuals manifesting persistent B19-associated
arthropathy but not in convalescent serum (von Poblotzki et al., 1995a) thus sug-
gesting a differential host response in these cohorts. However, similar NS1 anti-
body reactivity in patients with either chronic or acute B19-associated arthropathy
(Mitchell et al., 2001) and recently infected healthy individuals (Searle et al., 1998;
Ennis et al., 2001; Mitchell, et al., 2001; Heegaard et al., 2002b). Von Landenberg
et al. (2003) have suggested that B19 may be directly involved in the induction of
autoimmune reactions mediated, at least in part, by anti-phospholipid antibodies
because of the prevalence of these antibodies in persistently B19-infected individ-
uals.
Chronic infection with B19 may be of significance in pregnancy because, it can
be speculated that, the altered maternal immune status may facilitate re-activation
of viral infection (Bu¨ltmann et al., 2005). However, the clinical significance of
chronic B19 infection is often unclear. Chronic infection may be due to the fact that
B19 DNA persists in bone marrow, peripheral blood and synovial tissues of pa-
tients with chronic B19-associated arthropathy (Foto et al., 1993; Musiani et al.,
1995; Toivanen, 1995). However, it has also been shown that although B19 DNA
persisted in the synovium tissue of 28% of children presenting with chronic ar-
thritis, an even higher proportion (48%) of seropositive immunocompetent vol-
unteers had B19 DNA in their synovium tissues. These data suggest that B19 DNA
in synovial tissue may be indirectly associated with symptoms of chronic art-
hropathy. None of the individuals tested had evidence of B19 DNA in synovial
fluid, bone marrow or blood and all were positive for B19 IgG antibodies (Sod-
erlund et al., 1997). Nonetheless, a recent report further enhances the correlation
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between B19 infection and rheumatic childhood disease (Lehmann et al., 2003).
This work clearly elucidates a significant difference in serum and/or synovial fluid-
derived B19 DNA (Po0.0001) between control (9/124; 7%) and patient (26/74;
35%) specimens and concludes that the rate of persistent B19 infection in these
patients is significantly higher than in age-matched controls. However, the recent
finding of B19 DNA in 64% (14/22) of control skin biopsies compared to 50% (18/
36) of chronic urticaria patients confirms that caution should be exercised in
drawing conclusions regarding B19 involvement in skin disorders, and possibly in
other B19-associated clinical disorders (Vuorinen et al., 2002).
B19 infection and pregnancy
Exposure to, and infection with B19 can lead to serious complications during
pregnancy (Fig. 1). Infection during pregnancy may result in foetal anaemia,
spontaneous abortion and hydrops foetalis (Brown et al., 1984; Kinney et al., 1988;
Heegaard and Hornsleth, 1995). Seroprevalence studies have shown that approx-
imately 30–40% of women are not immune, therefore do not possess B19 anti-
bodies, and are consequently at risk of B19 infection. A vertical transmission rate
of 33% has been reported by the United Kingdom Public Health Laboratory
Service (PHLS, 1990) and similar rates have been reported in other studies (Brown
et al., 1984; Hall et al., 1990), although a recent report has disclosed a transmission
rate of 51% (Yaegashi, 2000). On the basis of 4 million births occurring in Europe
per annum (Eurostat, 1998), an average B19 seronegativity of 30% among preg-
nant women and a seroconversion rate for women of child-bearing age of 0.1–1%,
it can be estimated, that up to 14,000 women will seroconvert during pregnancy.
About 20% of B19 infections in pregnancy are thought to result in foetal loss, thus
implying that 2800 incidences of foetal death will occur each year, in Europe, as a
consequence of B19 infection (Levy et al., 1997; Miller et al., 1998; Wattre et al.,
1998). This figure is based solely on live births and as the number of actual preg-
nancies is much higher, the above estimate is conservative. Based on overall birth
rates, similar incidences of foetal death due to B19 infection can be predicted for
the US and Canada.
Pregnant women are most susceptible to B19 infection during epidemics and
also when exposed to recently infected children in the home (Valeur-Jensen et al.,
1999). During outbreaks, transmission rates of 25% in the school and 50% in the
home have been reported (Anderson et al., 1990). It is somewhat unfortunate that
most pregnant women acutely infected with B19 remain asymptomatic (Fig. 1),
however some do experience symptoms such as exanthema and arthralgia (Ko-
mischke et al., 1997; Enders et al., 2004). As these symptoms are commonly as-
sociated with pregnancy, acute B19 infection can often be overlooked, however
routine analysis of maternal immune status with respect to B19 infection would
overcome this problem. Although open to debate, we propose that pregnant
women should be carefully monitored during pregnancy for acute B19 infection
due to the high level of seroconversion in young women and because infection with
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B19 during pregnancy can lead to spontaneous abortion or foetal anaemia. Given
the availability of standardised and reliable diagnostic test systems, such screening
should be relatively straightforward to implement.
Foetal death usually occurs 4–6 weeks postinfection but has been reported up
to 12 weeks after B19 symptomatic infection (Hedrick, 1996). A study of 427
pregnant women with B19 infection in the UK found that foetal loss was limited to
the first 20 weeks of gestation (Miller et al., 1998). This is supported by figures
released in the UK and other studies which reported that foetal loss as a conse-
quence of intrauterine B19 infection is highest in, but not restricted to, the first 20
weeks of gestation (PHLS, 1990; Hall, 1990). The outcome of one of the largest
prospective studies of foetal complications as a result of serologically confirmed
maternal B19 infection (n ¼ 1018 individuals) was published in 2004 and provides
some of the most important information to those involved in the management of
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Exposure to Parvovirus B19 during Pregnancy 
(Inter-personal contact or blood products).
Symtomatic or Asymptomatic Infection 
may occur.
Maternal B19 serology 
and virology
Monitor carefully 
Re-test?
B19 Negative
Ultrasound, fetal hemoglobin,
hydrops fetalis? 
Acute B19 Infection 
Symptomatic
Routine ultrasound may detect 
fetal hydrops. 
Asymptomatic
Severe fetal hydrops:
Consider intrauterine transfusion
Fetal demise
Fetal survival
Unsuccessful
Successful 
Parvovirus B19 Infection in Pregnancy- Possible Outcomes 
Fig. 1 Parvovirus B19 infection in pregnancy—possible outcomes. Exposure to B19 during pregnancy
may result in either symptomatic or asymptomatic infection. Symptomatic infection can generally be
identifed by B19 serological or virological analyses. In the case of asymptomatic maternal infection,
ultrasound and foetal haemoglobin determination will be required to diagnose foetal hydrops, in ad-
dition to B19 DNA detection. Recent evidence indicates that intrauterine foetal transfusion may be an
important tool in the successful treatment of severe fetal hydrops (Enders et al., 2004).
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B19-infected maternal infection (Enders et al., 2004). Over a 5-year period
(1993–1998), B19 infection was serologically confirmed in 1018 pregnant women,
73% of whom presented without the classical symptoms of B19 infection such as
rash and arthropathy. The incidences of hydrops foetalis and foetal death were
3.9% (40/1018) and 6.3% (64/1018), respectively with all foetal deaths occurring
prior to 20 weeks gestation (11%; 64/579). The risk of foetal hydrops was highest
when infection occurred during gestation weeks 13–20 (7.1%; 23/322). Intrauterine
foetal transfusions were administered in 13/23 cases of severe foetal hydrops and a
survival rate of 85% (11/13) was observed. Strikingly, no foetal survival was ev-
ident in the remaining 10/23 cases of severe foetal hydrops where intrauterine
transfusion was not administered. Thus one of the major findings of this study has
been that prompt intervention, via intrauterine transfusion following confirmation
of severe foetal hydrops, can contribute to a reduction in the rate of foetal death
(Fig. 1) (Enders et al., 2004).
Anaemia is, therefore, a key underlying factor in the development of hydrops.
Foetal hydrops was initially associated with B19 infection in 1984 (Brown et al.,
1984). Since then, 10–20% of cases of NIHF have been reported to be B19 as-
sociated (Yaegashi et al., 1994; Jordan, 1996), and in a study of B19 infection in
Japanese women during pregnancy, the risk of hydrops was determined to be about
10% (Yaegashi et al., 1999). NIHF usually occurs 2–4 weeks after maternal B19
infection (Komischke et al., 1997). Cases of IUFD associated with foetal hydrops
and caused by B19 have been most commonly reported in the second trimester and
to a lesser extent in the third trimester of pregnancy (Sanghi et al., 1997). When
cases of IUFD occurring during an 18-month period in the UK were examined it
was discovered that 11 deaths were caused by B19 in the second trimester, and of
these only three were hydropic (Wright et al., 1996). In a separate study over a 16-
year period, 10 cases of IUFD were reported which were presented in gestational
weeks 15–29. Of those cases, 90% of the fetuses were hydropic, 30–40% had as-
sociated heart failure and three of the maternal infections had been asymptomatic
(Morey et al., 1992).
The critical time of infection has since been narrowed down to the 16th week of
gestation (Yaegashi et al., 1999) with most cases of foetal loss due to B19 infection
reported in the second trimester (Enders and Biber, 1990; Torok, 1990; Wattre et
al., 1998). This susceptibility can be attributed, at least in part, to the relative
immaturity of the foetal immune response at this stage. More importantly though,
is the tropism B19 has for erythroid progenitor cells (Yaegashi, 2000) and the fact
that in the second trimester of pregnancy the lifespan of foetal red blood cells
(RBCs) is shortened and the RBC mass increases 3- to 4-fold during this period of
gestation (Rodis et al., 1988). During an infection, B19 replication occurs within
these cells which undergo apoptosis resulting in an inhibition of erythropoiesis
(Morey et al., 1993). As B19 replicates, cell lysis occurs causing erythroblastopenia
and therefore severe foetal anaemia, which may be fatal to the foetus. Indeed,
Norbeck et al. (2004) have recently demonstrated that VP2 protein alone, or com-
ponent peptides, have the potential to inhibit haematopoiesis both in and ex vivo
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and suggest its potential use for the treatment of diseases such as polycytemia vera.
However, direct inhibition of haematopoiesis by B19 VP2 may also be associated
with the pathogenicity of B19 infection towards the foetus via disruption of red
blood cell maturation.
Third-trimester foetal loss or IUFD caused by an acute B19 infection had not
been widely reported until recently. Skjoldebrand-Sparre et al. (2000) reported that
of 93 cases of IUFD examined, 7.5% had B19 DNA in the placental tissue in the
absence of foetal hydrops. None of the infected pregnant women in this study
showed any clinical symptoms of B19, which again reinforces the proposal of
routine screening for B19 exposure during pregnancy. Skjoldebrand-Sparre et al.
suggested that, in the past, B19-associated IUFD in the final stages of gestation
may have been overlooked due to inadequate diagnostic procedures and also the
difference in clinical features of third-trimester B19 infection. However, one of the
most unusual observations in these cases of IUFD was the lack of foetal hydrops
and the fact that many of the cases (5/7) had either delayed or absent B19 IgG
responses. Histopathological examination of the foetuses revealed no major ab-
normalities. Another report of non-hydropic third-trimester IUFD associated with
B19 infection has been published (Tolfvenstam et al., 2001a). Here, it was revealed
by PCR analysis, of the foetal or placental tissues, that 15% of IUFD was at-
tributable to B19 infection. This study also found delayed B19-specific antibody
responses, as the mothers involved had no serological evidence of an acute B19
infection. However, follow-up studies detected B19 antibody seroconversion within
6 months. Tissue samples exhibitied no signs of viral inclusions and immuno-
chemical analysis revealed no evidence of B19 proteins (Tolfvenstam et al., 2001a).
Although the concept of B19-induced third-trimester foetal loss data has proved
somewhat controversial (Crowley et al., 2001; Sebire, 2001), it undoubtedly further
illustrates the requirements for awareness of B19 pathogenesis and diagnostic B19
quantitative PCR screening during pregnancy. Furthermore, Nunoue et al. (2002)
strongly suggest that prospective studies to evaluate the relationship between time
of infection and IUFD, with and without signs of foetal hydrops, are necessary. In
fact, B19 PCR may be the most sensitive way of diagnosing intrauterine B19
infection especially since more than 50% of infected foetuses test negative for B19
IgM (Dieck et al., 1999).
Although follow-up of foetal status is generally recommended to take place for
up to 3 months following diagnosis of material infection, Nyman et al. (2005) have
reported a case of IUFD occurring 5 months after primary diagnosis of infection
and associated with prolonged B19 viraemia and the presence of serological mark-
ers. These authors have suggested that revision of current follow-up criteria may be
necessary if extended viraemia is a more common occurrence than heretofore
thought.
Rodriguez et al. (2002, 2005) have undertaken the analysis of NIFH in both
stillborn and livebirth autopsy scenarios. Following the evaluation of 840 stillborn
autopsies (Rodriguez et al., 2002), 51 cases of NIFH were observed which rep-
resented 6.07% of all stillbirths. Congenital infection, caused either by bacterial or
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viral infection was identified in 17 of the 51 cases of NIFH of which B19 was
uniquely identified in four cases (7.8%). In fact, B19 infection was the fifth most
prevalent of a total of 23 individually classified NIFH aetiologies by these authors.
Subsequently, Rodriguez et al. (2005) have also studied the aetiology of NIFH in
liveborn infants (n ¼ 429, 14-year period) who died soon after birth. Although a
similar incidence of NIFH was observed to the previous study (7.45%; 32/429), the
aetiology of B19-associated NIFH, in an individual with systemic infection and
myocarditis, was only 3.1% (1/32 cases). Given this lower incidence of livebirth
with B19-associated NIFH, these observations support the view that the effects of
B19 infection during pregnancy are more likely to result in either in utero foetal
death or the complete resolution of infection, with, or without, the administration
of appropriate therapies.
An unusual case of foetal demise, caused by B19 infection, has been described
by Marton et al. (2005). Here, despite the successful administration of multiple
foetal blood transfusions to prevent anaemia, foetal hydrops worsened and cardiac
enlargement was observed upon foetal echocardiographic analysis which resulted in
foetal death after delivery at week 31 of gestation. Subsequent autopsy found
evidence of liver fibrosis. In addition, cardiomegaly and cardiac failure was caused
by B19 infection and B19-infected cardiac myocytes, as shown immunohistochem-
ically, were found to have undergone apoptosis. Thus, therapeutic intervention is
not always successful.
Although rare, B19 infection occurs during twin pregnancies and while it ap-
pears that both twins are equally susceptible to infection, individual foetus survival
does occur (Wolff et al., 1999; Graesslin et al., 2005). Graesslin et al. have reported
an occurrence of one foetal death at week 13 with foetal hydrops evident in the
second twin. Following confirmation of B19 infection via B19 DNA detection in
amniotic fluid and maternal B19 IgG reactivity, in utero blood transfusion raised
foetal haemoglobin levels from 3.9 to 5.9 g/dl and, apart from transient my-
ocarditis, the twin survived and was born normally without any negative outcome.
While much focus has rightly been placed on foetal survival following B19
infection, maternal health may not go unaffected. Bu¨ltmann et al. (2005) have
recently described how peripartum cardiomyopathy (PPCM), a rare disorder
whereby left ventricular dysfunction, develops in late pregnancy or early puerper-
ium, may be associated with virus-associated inflammatory responses in myocytes.
These authors studied 26 cases of PPCM and analysed endomyocardiac biopsies
for a range of viral genomes and identified B19 (n ¼ 4), HHV6 (n ¼ 2), CMV
(n ¼ 1) and EBV (n ¼ 1) DNA in eight patients (30.7%). Borderline myocarditis
was evident in all cases and one B19 infected patient also exhibited dilated card-
iomyopathy with inflammation. Although a similar occurrence of viral DNA was
detected in control patients (30.3%), no inflammatory responses were evident.
Consequently, Bu¨ltmann et al. (2005) have hypothesised that changes to immune
function during pregnancy may facilitate reactivation of latent viral infection, or
potentiate the effects of a recent infection, resulting in inflammatory cardiomyopa-
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thy associated with viral infection. In any case, this study clearly shows the re-
quirement for virological assessment of PPCM cases.
To date, there is very little evidence to suggest that maternal B19 infections
increase the risk of congenital anomalies and generally B19 is considered to be
embryocidal rather than teratogenic. However, there have been case reports of
central nervous system, eye and craniofacial anomalies (Markenson et al. 1998;
Levy et al., 1997).
Immunity to B19 infection
Antibody-mediated immune response
Upon exposure of immunocompetent individuals to B19, high-titre B19 viraemia
usually occurs within 1 week and lasts about 5 days with virus titres peaking on the
first 2 days. B19-specific IgM antibodies are detected late in the viraemic stage, on
about day 10–12 and can persist for up to 5 months postinfection (Anderson et al.,
1985; Schwarz et al., 1988; Yaegashi et al., 1989), but in some patients can last even
longer (Musiani et al., 1995). B19-specific IgG antibodies appear about 15 days
postinfection, remain elevated for many months and generally persist long term
(years). Antibodies against linear epitopes of the B19 VP2 protein and to some
extent VP1, disappear abruptly after B19 infection whereas IgG reactivity against
conformational epitopes of both VP1 and VP2 persist (Soderlund et al., 1995; Kerr
et al., 1999). B19 IgA antibodies are detectable for a short period following the
onset of clinical symptoms to B19 (Erdman et al., 1991) but have attracted little
attention as diagnostic markers of infection. The development of the B19-specific
antibody response corresponds with viral clearance and also, in the vast majority of
cases of B19 infection in immunocompetent individuals, protection from subse-
quent infection (Anderson et al., 1985)—although absolute confirmation of pro-
tective and neutralising B19-specific antibodies has yet to be established. However,
Serjeant et al. (2001) have shown that in children with sickle cell disease, only one
episode of B19-associated transient aplastic crisis (TAC) is ever detected, thereby
strongly suggesting an absence of re-infection.
The B19 VP1 protein, and in particular the VP1u, was thought to be the
immunodominant antigen. Moreover, its incorporation into serological assays was
thought essential (Rayment et al., 1990). However, it is now clear that this ob-
servation, which was based on the absence of antibodies to linear epitopes within
the VP2 protein, when screened by Western blot, is erroneous. It has now been
conclusively established that antibodies against capsid VP2 are maintained even
when B19 IgG directed against the VP1u is lost (Kerr et al., 1999; Manaresi et al.,
1999; Corcoran et al., 2000). Although, the key role of cellular immunity against
B19 infection is emerging (see the section on Cellular immunity), specific anti-viral
antibody is considered to represent a significant mechanism of immune protection,
based on the circumstantial evidence that high-dose immunoglobulin therapy is
sometimes beneficial in infected patients (Kurtzman et al., 1989b; Schwarz et al.,
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1990). Additionally, persistent infections associated with chronic anaemia have
been observed where the immune response to B19 has failed to produce neutralising
antibodies or they have been at very low levels (Kurtzman et al., 1987,1988; Cou-
lombel et al., 1989).
Cellular immunity
Cellular immunity to parvovirus B19 has not been studied as comprehensively as
the humoral response, predominantly due to the fact that antibodies were thought
to be the most important response in combatting B19 infection. Initial attempts to
demonstrate specific T-cell proliferative responses to B19 were unsuccessful (Kurtz-
man et al., 1989a) which for some time supported the prevailing theory that neu-
tralising antibody production alone conferred immunity to B19. Ex vivo B19-
specific CD4+ T-cells responses were first detected in 1996 against Escherichia coli-
expressed VP1, VP2 and NS1 antigens (von Poblotzki et al., 1996). T cell responses
of 16 individuals were analysed ex vivo (10 seropositive and six seronegative blood
donors), none of whom had evidence of acute infection. Of the seropositive cohort
stimulated with VP2, 90% displayed specific T-cell responses and 80% exhibited
VP1-specific responses. There was no significant difference in T-cell proliferation
for NS1 between seropositive and seronegative individuals. Upon inclusion of HLA
class I and II-specific monoclonal antibodies it was determined that HLA class II-
specific antibodies inhibited T-cell proliferation, indicating that the effector T-cell
population are CD4+ cells. Subsequent peripheral blood mononuclear cells
(PBMC) depletion of either CD4+ or CD8+ T cells and stimulation of the re-
maining population confirmed this observation.
Subsequent studies showed significant ex vivo T-cell reactivity in PBMC of
recently and remotely infected individuals using a B19 candidate vaccine (Franssila
et al., 2001) and also B19 recombinant proteins, VP1 and VP2 (Corcoran et al.,
2000). Recently infected individuals displayed very strong T-cell stimulation re-
sponses to the B19 capsids exhibiting average T-cell stimulation indices (S.I.) of 36
(Franssila et al., 2001). Blood donors with past infections gave comparable rates of
T-cell stimulation. Seronegative individuals had S.I. values of about 3.3 and this
study also showed that the responding population of T cells were CD4+. Although
von Poblotzki et al. (1996) found no difference in T-cell responses to NS1 in
seronegative and seropositive individuals, significant responses to this antigen have
been reported in both recently infected individuals and patients who developed
chronic arthropathy following B19 infection (Mitchell et al., 2001). T-cell responses
to NS1 were not seen in the group of healthy individuals with past B19 infection
except for two individuals who notably, were also NS1 IgG seropositive.
The cellular immune response to a 15-mer epitope of NS1 that is specifically
recognised by cytotoxic CD8+ T cells was investigated using major histocompat-
ibility complex (MHC) tetrameric complex binding (Tolfvenstam et al., 2001b). The
response of 21 individuals to this epitope was examined in healthy volunteers and
HIV-1-infected adults and children. Sixteen of the volunteers were HLA matched
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(HLA B35) and 6 were mismatched; 63% of matched individuals displayed specific
CD8+ T-cell responses; 72% of matched individuals in the same cohort exhibited
specific T-cell responses causing the production of interferon-g (IFN-g). The level of
B19-specific CD8+ T-cells was similar among healthy and HIV-infected individ-
uals. The results presented in this report showed the important cellular role of
cytotoxic T cells in combating B19 infection (Tolfvenstam et al., 2001b). Moreover,
B19-specific T-cell responses may now represent a novel method for confirming
past B19 infection.
Using a combination of ex vivo analytical approaches (e.g. IFN-g ELISpot and
51Cr-release assays following T-cell stimulation with peptides essentially represent-
ing the entire B19 proteome), Norbeck et al. (2005) have demonstrated that CD8+
T-cell responses are induced, and maintained for up to 2 years, following B19
infection of immunocompetent female individuals (n ¼ 5). Moreover, these authors
have also identified a number of HLA restricted CD8+ T-cell epitopes, most of
which are located within the B19 NS1 protein. These workers further showed that
while all individuals exhibited ex vivo IFN-g responses to NS1 peptides, only 2/5
individuals were responsive to VP2-derived peptides and none to VP1u peptides.
Norbeck et al. concluded that while CD4+-mediated immunity is directed towards
the B19 structural proteins, it appears that CD8+ cytotoxic immunity is primarily
directed against epitopes located within NS1 protein and postulated that B19 may
represent a model organism to explore temporally extended viral–host interactions.
The importance of evaluating T-cell responses in understanding the nature of
B19 infection was demonstrated recently by Chen et al. (2001). An AIDS patient
with persistent B19 infection was identified. An initial remission of B19 infection in
the patient was evident despite a lack of a specific antibody response, thus indi-
cating a role for cellular immunity in combatting B19 infection. In addition to this
case, NS1-specific lymphocytes have been detected in two B19 seronegative indi-
viduals who were exposed to B19, indicating a possible sub-clinical B19 infection or
perhaps a loss of antibodies against capsid proteins (Mitchell et al., 2001). Inves-
tigations by Tolfvenstam (Tolfvenstam et al., 2001b) identified two healthy
immunocompetent adults and two HIV-1-infected patients, seronegative for B19,
with specific CD8+ T-cell responses against B19 by either IFN-g ELISpot or
tetramer-binding studies, thus implying the presence of a cellular response in the
absence of a humoral response.
The production of a number of specific cytokines has thus far been associated
with B19 infection. Significant T-cell transcriptional activation has been reported in
a patient with acute B19 infection, causing increased levels of interleukin (IL)-1b,
IL-6 and IFN-g messenger RNA (mRNA) (Wagner et al., 1995). In a study of
recently infected children it was shown that although strong T-cell proliferative
responses were evident to both capsid proteins, production of the Th1 cytokine,
IFN-g, but not IL-2, was impaired when compared to convalescent adults (Co-
rcoran et al., 2000). Corcoran et al. also demonstrated that ex vivo T-cell responses
from B19 seropositive compared to seronegative individuals pregnant individuals
(n ¼ 149) exhibited significantly higher IFN-g levels for following VP1 (268+36
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versus 103+19 pg/ml; p ¼ 0.003) and VP2 (242+42 versus 91+16 pg/ml; p ¼ 0.01)
antigen stimulation. Significantly higher levels of IL-2 were also observed in B19
seropositive individuals following both VP1 (p ¼ 0.0003) and VP2 (p ¼ 0.0005)
stimulation (Corcoran et al., 2003). However this ex vivo production of IFN-g and
IL-2 observed in B19 seropositive pregnant women was lower than previously
observed for healthy non-pregnant individuals suggesting a possible diminution of
the maternal anti-viral immune response, which may subsequently increase the risk
of foetal B19 infection.
The effect of maternal immune status, during pregnancy, on B19 infection has
been further clarified by the work of Franssila et al. (2005) whereby weaker T-cell
proliferative responses and also specific cytokine secretions (IFN-g and IL-10) were
detected in recently infected pregnant women (n ¼ 3) compared to control and
recently infected non-pregnant women. In fact, there was no evidence of IL-10
production in the B19-infected pregnant individuals. Interestingly, one of the pa-
tients with no symptoms of infection displayed stronger IFN-g responses against
VP1/2 co-capsids than against VP2 capsids only, when compared to the other two
pregnant and B19-infected (symptomatic) individuals. Foetal loss occurred only in
the case of asymtomatic B19 infection and it could be hypothesised that the greater
reactivity to B19 VP1 epitopes, demonstrated by elevated ex vivo production of the
Th1 cytokine, IFN-g, may in some way be associated to this observation. Overall,
the relatively weaker T cell responses to B19 antigens during pregnancy, observed
by Franssila et al. (2005) is in accordance with the data and proposal of Corcoran
et al. (2003) that pregnancy may contribute to the pathogenicity of B19 infection
through attenuation of the anti-viral immune response.
Expression of the non-structural protein, NS1, causes the production of in-
creased levels of the inflammatory cytokine IL-6 in a number of cell lines including
hematopoietic cell lines and human umbilical vein endothelial cells (Moffatt et al.,
1996). IL-6 is known to be involved in synovial cell proliferation and in addition,
high levels of IL-6 along with other inflammatory cytokines have been found in
inflamed joints of patients with rheumatoid arthritis (RA), which would suggest an
association between IL-6 production and the joint manifestations observed with
B19 infection (Bataille et al., 1995). In addition to IL-6 production, high levels of
IFN-g, TNFa and IL-8 have been detected in the serum of infants with B19-
associated acute myocarditis (Nigro et al., 2000). There has been some evidence to
suggest that IL-2 production at the maternal–foetal interface of women who se-
roconvert during pregnancy will determine the outcome of the gestation. There was
a trend towards more CD3+ T cells and IL-2 secretion on the foetal side from
pregnancies with poor outcome, whereas IL-2 on the maternal side within the
intervillous space was associated with a favourable prognosis (Jordan et al., 2001).
Diagnosis of B19 infection
Extremely accurate laboratory diagnosis of recent B19 infection or past exposure
relies on testing (i) serum or plasma specimens for either specific antibody reactivity
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against viral capsid proteins, VP2 or VP1, expressed in eukaryotic expression sys-
tems (e.g. baculovirus-expression system) by ELISA or (ii) for B19 DNA in ma-
ternal or foetal tissues (e.g. amniotic fluid or blood) by qualitative or quantitative
PCR (Fig. 2). It is important to note that B19-specific immunoassays incorporating
E. coli-expressed B19 proteins only, which have undergone denaturation as part of
a manufacturing process, will produce false-negative results due to the absence of
conformational epitopes (Jordan, 2000) and the use of such systems should be
avoided in the interests of patient care. A specific advantage of the eukaryotic
baculovirus-expression system is its ability to enable the post-translational protein
folding necessary for the generation of soluble VP2 capsids (Fig. 3) (Brown et al.,
1990; Kerr et al., 1995a). Unlike B19 VP2, VP1 does not appear to form soluble
capsid structures, however, VP1 has been produced as a ‘conformationally intact’
protein which has been shown to retain conformational epitopes present in the
native virion (Brown et al., 1990; Kerr et al., 1999). Co-expression of VP1 and VP2
in eukaryotic expression systems has been proposed to result in the formation of
empty capsids, which are antigenically indistinguishable from native B19 virions.
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         PCR negative
Susceptible to infection
Monitor 
Parvovirus B19 IgM/IgG Screening
IgM negative 
IgG positive 
IgM positive
IgG negative 
IgM positive
IgG positive 
IgM negative
IgG negative 
PCR on amniotic fluid
             PCR positive
Maternal serum B19 DNA >104 IU/ml 
Recent infection  
Possible transmission to the fetus 
Past infection 
IgG confers immunity 
to infection
IgM indicates recent infection
Possible transmission to fetus 
Confirmatory testingfor B19 viral DNA 
by PCR
No evidence of past/recent 
infection 
Confirm with PCR of maternal  
serum
Fig. 2 Detailed serological and virological screening algorithim for the diagnosis of parvovirus B19
infection in pregnancy. Women who are exposed to parvovirus B19 should be assessed to determine if
they are susceptible to infection or have an acute infection. If a woman tests negative for parvovirus B19
IgM reactivity and positive for B19 IgG, the woman is immune and can be reassured that she will not
develop infection. If the woman is B19 IgG and IgM negative, the woman is not immune and could
develop infection. B19 PCR analysis will confirm maternal status. If the woman is positive for B19 IgM
and either positive or negative for B19 IgG reactivity, she has been recently infected and there is a risk of
a transplacental infection. B19 PCR analysis of the amniotic fluid will confirm transmission to the foetus.
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Furthermore, it has been hypothesised that such co-capsids contain conformational
epitopes essential for accurate detection of infection (Kajigaya et al., 1989, 1991;
Franssila et al., 2001; Ballou et al., 2003).
Evidence has recently emerged that B19 NS1 IgG and IgM detection may also
contribute to the diagnosis of acute B19 infection, thereby supplementing the de-
tection of B19-specific antibodies, reactive towards B19 capsid antigens, as diag-
nostic markers of B19 exposure (Ennis et al., 2001; Heegaard et al., 2002b).
Detection of b19 IgM
Acute B19 infections can be detected and confirmed by the presence of B19-specific
IgM reactivity while past infections are detected by IgG reactivity (Anderson et al.,
1985) (Fig. 2). Generally, IgM antibodies appear 7–10 days postinfection and are
directed against linear and conformational epitopes of VP1 and VP2 (Palmer et al.,
1996; Manaresi et al., 2001).
Only one B19 IgM diagnostic test is available that has been approved by the
United States Food and Drug Administration (FDA) for the detection of B19-
specific IgM as a marker of recent infection in pregnancy. This test system is a m-
capture enzyme immunoassay (EIA) that utilises highly purified recombinant B19
VP2 capsids (Fig. 3) for the detection of B19-specific IgM in either human serum or
plasma. The immunoassay has a sensitivity of 89.1% and a specificity of 99.4%
(Doyle et al., 2000) and is extensively used for the diagnosis of recent B19 infection
(Jordan, 2000; Mitchell et al., 2001; Vuorinen et al., 2002). Validated alteration of
the immunoassay cutoff, based on receiver operating charcterisitic (ROC) analysis
can accommodate superior immunoassay sensitivity (>89.1%) which may have a
utility in the detection of lower levels of B19-specific IgM in pregnancy, immuno-
compromised individuals and young children (Doyle et al., 2000). Of special sig-
nificance is the observation that no evidence of cross-reactivity with antibodies
specific for other pregnancy-related viral infections (e.g. rubella, mumps, varicella
zoster virus, cytomegalovirus and herpes simplex virus-1 (HSV-1)) and HSV-2 is
apparent when this immunoassay is used in clinical settings. Although at present
there is no international standard preparation for B19 IgM, the widespread uti-
lisation of this immunoassay system means that inter-laboratory results can be
compared with confidence. It should be stated that previous studies have reported
cross-reactivity with rubella in several commercial B19 IgM assays (Sloots and
Devine, 1996; Tolfvenstam et al., 1996) and as the symptoms of rubella infection
are similar to those of B19 infection this was a cause for concern, particularly in the
diagnosis of infection in pregnant women. A 5% false-positive rate was reported
when specimens from healthy volunteers were analysed with a range of commer-
cially available B19 IgM immunoassays, probably due to cross-reactivity and the
lack of specificity in these immunoassays (Tolfvenstam et al., 1996). However, as of
2005 many of the systems employed in these studies are no longer available.
Beersma et al. (2005) have shown that B19 DNA levels in sera exhibit signif-
icant correlation with the presence of B19 VP2-reactive IgM (Pearson coefficient,
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r ¼ 0.44). Moreover, these authors have demonstrated that in sera with B19 DNA
loads greater than 106 IU/ml, B19 IgM reactivity (as defined by specimen/assay
cutoff ratio) always exceeds 3.0. Thus, it is clear that the presence of B19 VP2 IgM
antibodies in sera is predictive for the presence of B19 DNA. Beersma et al. also
evaluated differential antibody reactivity between B19 VP1 and VP2 antigens and
suggest that because only low levels of B19 DNA were present in the small number
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Fig. 3 Parvovirus B19 capsids. Electron microscopic image of B19 capsids, comprising recombinant
B19 VP2 only, which are produced using the baculovirus expression system. These capsids are utilised in
FDA approved serological assays to detect B19 IgM and IgG. Courtesy of Biotrin Limited, Dublin,
Ireland.
B19 in Pregnancy 189
of sera (4/212) which were B19 VP1-only IgM reactive that B19 VP2 IgM is suf-
ficient to detect highly B19 viraemic sera. These observations represent extremely
useful information in a clinical context as they represent the first data correlating
viral load with B19 IgM antibody levels.
Some reports have suggested that IgM directed against conformational
epitopes on VP1 and VP2 proteins, and against linear epitopes on VP1, are pro-
duced at the same time postinfection and with identical frequencies. However, it
has also been suggested that IgM reactivity against the minor capsid protein, VP1,
may persist somewhat longer postinfection (Palmer et al., 1996; Manaresi et al.,
2001). Thus, should IgM responses against conformational VP1 persist at a time
when other B19-specific IgM antibodies are absent, then diagnostic techniques
incorporating conformational VP1 may not be the most suitable marker of acute
B19 infection. However, other work could elucidate no difference in IgM reactivity
against conformational epitopes of the capsid proteins in diagnosing B19 infection
(Kerr et al., 1999). Furthermore, these authors observed no differences in IgM
reactivity against native (conformationally intact) antigens and linearised antigens
for either VP1 or VP2.
Although detection of B19 NS1 IgM has received little attention as a marker of
recent infection with parvovirus B19, Ennis et al. (2001) observed that 27.5% (11/
40) of specimens that were B19 VP2 IgM positive also contained B19 NS1 IgM
when tested by ELISA. Interestingly, when these samples were analysed by Western
blot there was no evidence of NS1 IgM reactivity which indicates that conformat-
ional epitopes of the NS1 protein may be important for detection.
Detection of B19 IgG
After exposure to B19, the appearance of B19 IgG antibodies coincides with di-
minishing IgM antibody response, and B19 IgG reactivity against conformational
epitopes of VP1 and VP2 persists postinfection (Fig. 2). However, for both capsid
proteins, reactivity against linear epitopes declines postinfection, abruptly against
VP2 but more slowly against VP1 (Soderlund et al., 1995; Kaikkonen et al., 1999;
Kerr et al., 1999; QA :4Manaresi et al., 1999)—an observation which has significant
consequences for diagnosis. Antibody reactivity against linear VP2 epitopes, pre-
dominantly directed against a heptapeptide (amino acids 344–350) identified by
analysis of acute-phase sera (Kaikkonen et al., 1999), usually disappears within 6
months of B19 infection (Soderlund et al., 1995). Thus detection of B19-specific
IgG, directed against linear epitopes of VP2, may assist in timing B19 exposure to
within a 6-month period.
Although the antibody response wanes against linear epitopes on B19 capsid
proteins it persists against conformational epitopes of both capsid proteins. Only
one FDA approved B19 IgG immunoassay is available to detect B19 IgG as a
marker of past infection (Corcoran et al., 2000). This microplate immunoassay
which utilises capsid VP2 to detect B19 and erythrovirus V9 (genotype 3) IgG
(Heegaard et al., 2002a; Candotti et al., 2004; Corcoran et al., 2005b) (Fig. 3). In
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studies undertaken to fulfill FDA approval criteria, inter-assay reproducibility data
for this B19 IgG-specific immunoassay was determined by blinded analysis of a
panel of unreactive, weakly reactive and reactive B19 IgG specimens (n ¼ 16)
across three separate manufactured lots of the immunoassay, at three test sites,
over a 3-day period. Consequently, each specimen was assayed three times per day
(in duplicate) per lot, on three different days, at each of the three laboratories
(n ¼ 81 assays per specimen). Total inter-assay reproducibility was excellent, and
% coefficient of variation (%CV), ranged from 11.2 to 21.8%CV or 15.6 to
26.8%CV when expressed in terms of either immunoassay index (specimen/cutoff
ratio) or OD values, respectively. Linear regression analysis of inter-site data con-
firmed the high reproducibility and robustness associated with the B19 IgG-specific
immunoassay and correlation coefficients of 0.99 were observed for both index and
OD values, respectively, for both inter-site (site 1 versus 2, site 2 versus 3 and 1
versus 3) and all inter-lot comparative scenarios. Comparative studies of this ba-
culovirus-based immunoassay to another commercially available E. coli-based VP1
immunoassay for the detection of B19 antibodies in pregnant women have been
undertaken and confirmed the accuracy of diagnosis, and absence of equivocal
results, of the VP2 capsid immunoassay system (Jordan, 2000). The availability of a
B19 IgG international standard (2nd International Standard 2003; code 01/602; 77
IU/ampoule) further contributes to the accurate confirmation of past B19 infection
by standardising B19 IgG determination from different laboratories using different
test systems (Ferguson et al., 1997; Searle et al., 1997).
Candotti et al. (2004) have recently presented controversial data which sug-
gested that enzyme immunoassays utilising B19 VP2 capsids derived from genotype
1 did not detect a subset of erythrovirus genotype 3 (V9)-derived IgG. These find-
ings have been disputed (Corcoran et al., 2005b) and work is currently underway to
resolve this significant issue. Initial data (not shown) from analysis of blinded
specimens suggest that B19 VP2 capsids can indeed detect all V9-derived IgG, a
finding which confirms the diagnostic utility of this validated immunoassay system
and that VP1 presence is not necessary to diagnose B19 infection.
The importance of NS1-specific IgG merits consideration with view to im-
proved diagnosis of acute B19 infection. Although the presence of B19 NS1 IgG
was originally proposed to be associated with persistent B19 infection (von Po-
blotzki et al., 1995a, b), it now appears to be the case that no significant difference
between the level of NS1 IgG in control patients with past infection and those with
chronic B19 infection is evident (Searle et al., 1998; Venturoli et al., 1998; Jones et
al., 1999). In addition, Tolfvenstam et al. (2000) have mapped B-cell epitopes on
NS1 and identified three antigenic regions (amino acids 191–206, 271–286,
371–386), which exhibited equal reactivity towards antibodies from healthy indi-
viduals with past B19 infection and B19-persistently infected patients. Hemauer et
al. (2000) showed that NS1 IgG reactivity was most prevalent in serum following
recent infection in pregnant women (61%) which, in turn, was supported by the
work of Mitchell et al. (2001). Mitchell et al. examined NS1 IgG reactivity in sera
from a range of cohorts (i.e. individuals (i) infected with B19, (ii) who had been
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exposed to B19 but were not infected, (iii) who were suffering from a rash illness,
chronic arthropathy or (iv) were healthy controls) and observed that NS1 IgG
reactivity was predominant in recently infected specimens. Moreover, when sub-
sequent specimens from these individuals were analysed, the level of NS1-specific
IgG reactivity had declined. In addition there was no evidence of a correlation
between NS1-specific IgG and the onset or development of arthropathy (Mitchell et
al., 2001). Ennis et al. (2001) demonstrated that 69% of children recently infected
with B19 were NS1 IgG seropositive and Heegaard et al. (2002b) also observed a
seroprevalence of 60% B19 NS1 IgG in recently infected individuals (o6 weeks
postinfection) and suggest that NS1 IgG detection may significantly improve
immunoassay sensitivity. Thus as the NS1-specific IgG response diminishes, as the
virus is cleared, NS1 IgG reactivity may contribute to accurate diagnosis as a
marker of recent infection, in parallel with the detection of IgG against linear
epitopes on VP2 (Ennis et al., 2001).
In summary, detection of B19-specific IgM indicates recent infection with B19
and B19 IgG detection confirms past exposure. Detection is optimal in immuno-
assays utilising VP2 capsids for antibody detection. Antibody detection against B19
NS1 protein may contribute to the confirmation of recent B19 infection but only
when in association with standardised VP2 capsid-based immunoassays. Genotype
3 (erythrovirus V9) antibody detection is also feasible using immunoassays based
on B19 VP2 capsids.
B19 DNA detection by PCR
Without doubt, the most sensitive method of diagnosis of B19 infection in preg-
nancy is the detection of B19 viral DNA in maternal–foetal blood or tissue by
PCR. Many clinical laboratories now provide parallel B19 antibody screening and
diagnostic PCR which greatly improves the sensitivity of detection of B19 infection
(Skjoldebrand-Sparre et al., 2000; Manaresi et al., 2002). However, caution must be
exercised with regard to the deployment of B19 PCR for a number of reasons: (1)
the high viral titres associated with B19 infection may cause cross-contamination of
samples and hence cause PCR false positivity. This is particularly problematic
when nested PCR is used for B19 detection. (2) Low levels of B19 DNA may
remain in the host long after infection thus, B19 DNA detection may not always be
indicative of an acute infection. B19 viral titres can reach greater than 1012 genome
equivalents per ml (ge/ml) (Prowse et al., 1997) during the stage of acute infection.
In healthy, immunocompetent individuals viral DNA is detectable for at least 1
month postinfection (Erdman et al., 1991) but has also been shown to persist at low
levels for long periods (Cassinotti et al., 1993; Kerr et al., 1995b; Musiani et al.,
1995; Cassinotti and Siegl, 2000). In cases of chronic B19 infection, viral DNA can
persist in the host without the presence of B19-specific IgM or IgG (Kurtzman et
al., 1988; Frickhofen et al., 1990). Thus, B19 DNA detected by qualitative PCR
analysis is not always indicative of recent infection. In fact, quantitative PCR was
used by Cassinotti and Siegl (2000) to determine the amount of B19 viral DNA in
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an immunocompetent patient from the time of acute B19 infection until conva-
lescence. Over a 1-year period a series of blood samples were taken and analysed
using a real-time PCR analysis. The B19 viral titre reached levels of 8.8 109 ge/ml
of blood during the viremic stage of infection. At this point the patient was positive
for B19-specific IgM but had no evidence of IgG reactivity. By week 164 the viral
load had declined to 95 ge/ml, IgM reactivity was lost and IgG reactivity against
B19 capsid proteins was strong. Subsequent specimens taken had no detectable B19
DNA. Thus, while the actual amount of circulating B19 DNA present following
B19 infection diminished dramatically after the first few weeks of infection, it
persisted for some time before being cleared from the host despite the development
of circulating B19 IgG. This slow rate of B19 DNA clearance from an immuno-
competent host could have a negative impact on PCR as a diagnostic tool in
differentiating between recent and chronic B19 infection in a situation where a
qualitative PCR assay, of unspecified sensitivity of detection is employed. (3) Many
PCR assays are developed in-house and employ primer pairs of undefined sensi-
tivity of detection. (4) Many extraction methods are suitable for DNA purification
from serum or plasma only and not from solid tissue (e.g. placenta or foetal tissue).
(5) Finally , false negativity may be observed with respect to non-B19 strains (e.g.
erythrovirus V9, K71 or A6) due to minor sequence differences (Hokynar et al.,
2002; Nguyen et al., 2002; [Servant et al., 2002). An in-house nested PCR assay
capable of accurately detecting V9 and B19 DNA simultaneously has been devel-
oped (Heegaard et al., 2001), which comprises of a primary round of amplification
using a pair of consensus primers and a subsequent round of amplification using
separate primers for B19 and V9. Using this PCR assay, clinical samples, including
100 B19 IgM-positive specimens and untreated plasma pools representing 100,000
blood donor units from the Danish population, were screened for both V9 and B19
DNA. None of the specimens analysed were positive for V9 DNA, which may be
due to the fact that this V9 erythrovirus isolate is an emerging virus and may
actually be more divergent than previously thought (Heegaard et al., 2001).
PCR analysis has also revealed another B19 viral genotype, K71, which persists
in human skin and has a nucleotide divergence of 10.8% from B19 and 8.6% from
V9 (Hokynar et al., 2002). Many of the aforementioned issues associated with
‘home-brew’ PCR tests to detect the parvovirus B19 in clinical specimens can be
overcome with the use of commercially available test systems. Analysis of two
commercially available validated quantitative B19 PCR systems, the LightCycler-
Parvovirus B19 quantification kit (Roche Diagnostics; http://www.roche-diagnos-
tics.com/) and the RealArt Parvo B19 LC PCR (Artus; http://www.artus-bio-
tech2.com) was performed by Hokynar et al. (2004) to examine their ability to
detect, quantify and also differentiate between genotypes. The study revealed that
although the Roche system was capable of detecting genotype 1 DNA at high
sensitivity, it proved unsuitable for genotype 2, and to some extent, genotype 3
DNA detection. Conversely, the quantitative PCR system manufactured by Artus
proved equally efficacious with respect to genotype detection, although again, high-
sensitivity genotype 3 DNA detection was somewhat problematic. Schneider et al.
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(2004) and Liefeldt et al. (2005) have also recently reported high-sensitivity strat-
egies for quantitative detection and differentiation of all three erythrovirus gen-
otypes.
Notwithstanding these limitations, B19 PCR is an effective technique used to
detect B19 infection. In addition, with the introduction of the WHO International
Standard for Parvovirus B19 DNA (NIBSC 99/800), PCR assay standardisation
has become possible whereby B19 DNA units are quoted in International Units/ml
(IU/ml) (Saldanha et al., 2002). Using the WHO standard, a number of compatible
B19 PCR assay systems have been established (Daly et al., 2001; Mu¨ller et al., 2002;
Thomas et al., 2003) and, using real-time PCR technology, a sensitivity of detection
of 15.4 IU/ml (10 Baxter-Units/ml) was reached (Aberham et al., 2001).
Alternative detection methods
In cases of foetal infection and also in the immunocompromised host, when no
B19-specific antibodies are present, patient histology can be used to assist with the
confirmation of B19 infection in foetal tissue, whereby characteristic B19 inclusion
bodies can be visualised either by DNA hybridisation or by antigen-detection
techniques (van Elsacker-Niele, 1998). However, although these techniques are
specific, sensitivity of detection remains problematic (van Elsacker-Niele and
Kroes, 1999). Assays based on exploitation of the P antigen receptor of B19, known
as receptor-mediated hemagglutination (RHA), have been proposed as a cheap way
of screening plasma and apparently detect whole virus, however the assay sensi-
tivity is low when compared to PCR and, more importantly, it has not been as-
sessed in an obstetrics context (Cohen and Bates, 1995; Sato et al., 1995;
Wakamatsu et al., 1999). In cases where patients are treated with intravenous
immunoglobulin (IVIG) to treat chronic B19 infection, assessment of antigen-spe-
cific B cell memory allows one to discriminate IVIG- and individual-derived B19
IgG, which is important in determining the seroconversion status of the individual
(Corcoran et al., 2005a).
Elevated maternal serum alpha fetoprotein (MSAFP) levels have been asso-
ciated with foetal parvovirus B19 infection, probably due to damage to foetal liver
cells, thus MSAFP levels could potentially serve as an indirect indicator of foetal
infection (Carrington et al., 1987; Bernstein and Capeless, 1989). However, the
sensitivity of this test is unknown and as several cases have reported severe foetal
infection with normal levels of MSAFP (Saller et al., 1993; Johnson et al., 1994),
the association between elevated MSAFP levels and B19 foetal infection is weak
and, therefore, cannot be accepted as a reliable marker of infection.
The most reliable way to diagnose acute foetal infection is to detect B19 DNA
in amniotic fluid or foetal serum by PCR or viral particles by electron microscopy.
Clinical use of these tests however remains to be evaluated. Although B19 infection
can be diagnosed through PCR analysis of amniotic fluid obtained by am-
niocentesis, invasive diagnosis of infection is not required for all suspected/con-
firmed maternal infections. It must be noted that viral particles are only present at
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the viremic stage and the method used to detect these, an EIA, is generally in-
sensitive. The presence of B19 IgM in foetal blood cannot be depended on to make
a diagnosis of foetal infection as IgM appears in foetal circulation only after 22
gestational weeks (Rodis et al., 1988). Even beyond 22 weeks of foetal development
IgM diagnosis can present misleading false-negative results (Pryde et al., 1992).
Blood product safety and pregnancy
Currently, there is no strategy for the best management of foetal hydrops caused by
B19 infection during pregnancy but many cases are treated with intravascular
transfusion. In a survey of maternal–foetal medicine specialists involving 539 cases
of B19-induced hydrops, death occurred after intrauterine transfusion in 6% of
cases, and in 30% of cases without intrauterine transfusion (Rodis et al., 1998).
Treatment of B19 infection with transfused blood is not always effective and it is
imperative that one is cognisant of the potential presence of high titre B19 virus in
blood products (Prowse et al., 1997; Santagostino et al., 1997).
Screening of blood donations for the presence of B19 DNA is not routine
(Blumel et al., 2002) despite the fact that this virus is highly resilient and can
withstand denaturation even at high temperatures (Santagostino et al., 1994). In
fact, B19 is thought to withstand processes involving solvent–detergent treatment,
lyophilisation and temperatures of 100 1C for 30min, and despite these harsh
virucidal processes, still have the capacity to contaminate factor VIII and factor IX
concentrates (Santagostino et al., 1997). B19 contamination of such purified blood
products is particularly problematic as, in the absence of B19 IgG, the infectious
potential of B19 may be enhanced (Blumel et al., 2002). The most-recent deter-
mination of B19 prevalence is 1 in 837 blood donations (n ¼ 5025, range 7.1 104
to 2.1 1012 IU B19 DNA/ml) (Henriques et al., 2005) Previously, B19 levels had
been estimated to be present in 1:16,000 transfusions based on the average inci-
dence of B19 in a non-epidemic period (320 cases per 100,000 population) and the
fact that viraemia lasts about 7 days (Prowse et al., 1997). During epidemics the
incidence of viraemia in donations is greatly increased with levels reported as high
as 1:167 in Japan (Yoto et al., 1995).
The infectious level of parvovirus B19 in blood products has yet to be estab-
lished with certainty and is likely to depend on the amount of neutralising B19 IgG
co-present in the product, in addition to recipient immune status. As part of a
phase IV study, a group of 100 healthy volunteers, seronegative for B19, were given
1 unit of plasma that had been solvent/detergent treated (Davenport et al., 2000).
Of the volunteers subsequently screened for incidences of B19 infection, 18% had
seroconverted over the subsequent 3 months. Three of the 10 batches of plasma
used in the study were retrospectively found to contain high levels of B19 (>107 ge/
ml) and these batches coincided with the plasma administered to the volunteers
who seroconverted. Interestingly, batches with low amounts of B19 (o104 ge/ml)
did not cause B19 seroconversion. Presently, plasma lots containing high levels of
B19 are eliminated from manufacturing batches of plasma. Thus, there is a level of
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virus, as yet undetermined, that will not cause B19 infection. Notably, Daly et al.
(2002) undertook a retrospective study of similar plasma pools (n ¼ 30) to those
utilised in the study of Davenport et al. (2000) and found B19 IgG levels in the
range 64.7+17.5 IU/ml. Thus it is possible that this level of B19 IgG may be
capable of preventing recipient B19 infection when transfused with plasma con-
taminated with low levels of parvovirus B19 (o104 ge/ml). Blumel et al., 2002
however, identified two incidences of B19 transmission by separate lots of clotting
factor concentrates, one with 8.6 106 ge/ml (volume: 180ml) and the other shown
to have 4 103 ge/ml B19 DNA (volume: 966ml), which were responsible for se-
roconversion.
Despite the fact that B19 infection can be transmitted via contaminated blood
products, regulatory requirements relating to B19 contamination of pooled plasma
or blood products prior to product release have only recently been implemented.
The European Pharmacopoeia now stipulates that B19 DNA levels must be less
than 104 IU/ml in plasma pools destined for anti-D IgG manufacture (European
Pharmacopoeia, 2004). However, it should be acknowledged that many manufac-
turers now perform B19 PCR on plasma mini-pools to eliminate high B19 viral
load plasma (Aberham et al., 2001) and many blood banks supply this upon re-
quest under the designation ‘Parvo-safe blood’. PCR screening of blood products
has been shown to facilitate removal of 23 B19 PCR-positive donations from a
plasma pool of 6000 resulting in a 10–100-fold decrease in viral load (Prowse et al.,
1997).
Nonetheless, the issue of whether high-risk populations, such as pregnant
women, immunocompromised patients and people with chronic anaemia, should
undergo administration of any B19-containing products while the level of infec-
tious B19 DNA is unknown, and minipool screening is not mandatory, must be
addressed. The aforementioned availability of an international standard prepara-
tion of B19 DNA (Saldanha et al., 2002) in addition to a number of compatible and
quantitative B19 PCR detection systems (Aberham et al., 2001; Daly et al., 2002;
Knoll et al., 2002; Mu¨ller et al., 2002; Thomas et al., 2003), should alleviate prob-
lems caused by ambiguity between results from laboratories using various methods
of measuring and expressing B19 DNA levels and help determine the infectious
dose for parvovirus B19.
Treatment and vaccination
Parvovirus B19 infection is self-limiting in the immunocompetent host and, there-
fore, no specific therapy is required for such individuals. However, in cases where
individuals suffer from arthritic complications, symptoms can be treated with non-
steroidal anti-inflammatory drugs. The administration of high-titre IVIG has
proven successful in the treatment of patients with chronic infection but this is
expensive and remission may be temporary in the immunocompromised host
(Kurtzman et al., 1989b; Fukushige et al., 1995; Lui et al., 2001). In addition, IVIG
treatment does not work in all cases and no data is available on the actual pro-
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tective level of B19 IgG although levels greater than 6 IU/ml are thought to be
protective (Searle et al., 1997). For cases of foetal infection, intrauterine blood
transfusions may be beneficial especially in the case of hydrops but this procedure
does involve additional risks to the outcome of pregnancy (Berry et al., 1992;
Cameron et al., 1997; Bousquet et al., 2000; Enders et al., 2004).
If B19 infection occurs during pregnancy, the pregnancy should be allowed to
proceed but carefully monitored. In cases of mild hydrops or with evidence of
resolution of hydrops, foetuses should be closely monitored by ultrasound to detect
any signs of hydrops, oedema, ascites and effusions (Morgan-Capner and Crow-
croft, 2002). If hydrops worsens, a diagnostic cordocentesis and foetal blood
transfusion should be considered. Currently, primary management of hydropic
foetuses is cordocentesis to assess foetal haemoglobin and reticulocyte count, and
intrauterine transfusion, if necessary (Markenson et al., 1998). A reticulocyte count
in a foetal blood sample could provide evidence of bone marrow recovery. At
present there is no reliable way to predict prognosis for individual foetuses and
termination of pregnancy should not be recommended (Barrett et al., 1994). At
delivery, examination of the cord blood for B19 IgM will reveal whether the virus
has crossed the placenta and infected the foetus. The child should be carefully
followed up for several weeks to check for any delayed sequelae.
The administration of high-titre IVIG has proven successful in treating foetal
hydrops in some cases (Selbing et al., 1995; Alger, 1997). Alternatively, clinical
symptoms of infection have been treated effectively by intrauterine blood trans-
fusions (Schwarz et al., 1988; Hansmann et al., 1989). A study by Wattre´ reported
two cases where intrauterine blood transfusions led to the cessation of symptoms
and to the birth of normal babies (Wattre et al., 1998). In a separate study, 38 cases
of B19-associated foetal hydrops were reported, 12 of whom received intrauterine
blood transfusion. Although three of these foetuses subsequently died, the prob-
ability of death among fetuses that did not receive a blood transfusion was sig-
nificantly higher (Fairley et al., 1995). In addition, spontaneous resolution of
hydrops without intervention has been reported thus suggesting that treatment is
not always necessary (Pryde et al., 1992).
Infection with B19 and rubella can be detrimental to the foetus if the mother is
infected during pregnancy. However, primary infection with rubella in the first
trimester of pregnancy is associated with a high risk of congenital abnormalities
(Gibbs and Sweet, 1994; Pastuszak, 1994) unlike B19 infection, which is most likely
to affect the foetus adversely during the second or third trimester (Tolfvenstam et
al., 2001a). As both infections present with similar symptoms, it is essential to
distinguish between the two infections to decide upon the appropriate course of
action.
The major finding that intrauterine foetal transfusion to treat severe foetal
hydrops was associated with 85% foetal survival and that no foetal survival was
apparent in the absence of intrauterine transfusion (Enders et al., 2004) is perhaps
the most compelling evidence that this therapeutic strategy should be given serious
consideration should B19 infection occur during pregnancy.
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As of 2005, there is no effective vaccine against B19 infection available for
either seronegative pregnant women or for immunosuppressed individuals. A pos-
sible candidate vaccine comprising baculovirus-expressed B19 empty virus-like
particles (VLP) is presently under evaluation which is the first B19 vaccine to reach
human trials and is sponsored by MedImmune, Inc (Gaithersburg, MD) (Bansal,
1993). Ballou et al. (2003) have recently shown that the recombinant vaccine
(MEDI-491; Medimmune), comprises B19 VP1 and VP2 capsid proteins, could
elicit neutralising antibody titres in volunteer adults (n ¼ 24). Sera from immunised
individuals was also shown to be capable of inhibiting in vitro B19 replication. The
efficacy of this formulation to prevent infection with parvovirus B19 remains to be
established, nonetheless it is an encouraging and welcome advance in the fight
against this insidious pathogen.
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